How many insider trades does FilingIQ track for PMN?

FilingIQ tracks 71 Form 4 insider transactions for PMN (ProMIS Neurosciences Inc.), covering filings from Jul 11, 2022 onwards. 6 of those were filed in the last 90 days.

Are PMN insiders net buyers or net sellers?

Across the full Form 4 history for PMN, 31 transactions (44%) were open-market purchases and 1 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PMN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is PMN in?

ProMIS Neurosciences Inc. (PMN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $34.63M.

PMN insider trading

NasdaqCM Healthcare

ProMIS Neurosciences Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

44% / 1%

Market cap

$34.63M

About ProMIS Neurosciences Inc.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Company website: www.promisneurosciences.com

PMN insider activity at a glance

FilingIQ has scored 71 insider transactions for PMN since Jul 11, 2022. The most recent filing in our index is dated Apr 22, 2026.

Across the full history, 31 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on PMN insider trades is 59.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live PMN trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for PMN?: FilingIQ tracks 71 Form 4 insider transactions for PMN (ProMIS Neurosciences Inc.), covering filings from Jul 11, 2022 onwards. 6 of those were filed in the last 90 days.
Are PMN insiders net buyers or net sellers?: Across the full Form 4 history for PMN, 31 transactions (44%) were open-market purchases and 1 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PMN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is PMN in?: ProMIS Neurosciences Inc. (PMN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $34.63M.

Methodology & sources

Every PMN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.